Journal Mobile Options
Table of Contents
Vol. 64, No. 2, 2010
Issue release date: August 2010
Eur Neurol 2010;64:65–73

Cerebral Glucose Metabolism of Parkinson’s Disease Patients with Mild Cognitive Impairment

Lyoo C.H. · Jeong Y. · Ryu Y.H. · Rinne J.O. · Lee M.S.
Departments of aNeurology and bRadiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, and cDepartment of Brain and Bioengineering, KAIST, Daejeon, Korea; dTurku PET Center, University of Turku, Turku, Finland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Half of Parkinson’s disease (PD) patients with mild cognitive impairment (MCI) develop dementia. We studied topographic distribution of cerebral hypometabolism in PD with different types of MCI. Methods: This study included 61 nondemented PD patients and 14 age-matched controls. PD patients were grouped into normal cognition (PD-NC, n = 20), single amnestic (PD-SA, n = 12), single nonamnestic (PD-SN, n = 11), and multidomain MCI (PD-MD, n = 18). Using [18F]-fluorodeoxy-glucose PET, cerebral glucose metabolism of MCI groups was compared with that of controls and the PD-NC group. Results: In comparison with controls, PD-NC and PD-SA groups showed no hypometabolic brain areas. However, the PD-SN group showed hypometabolism in parieto-temporo-occipital cortices. The PD-MD group showed widespread hypometabolism that predominantly involved parieto-occipital cortices. In comparison with the PD-NC group, only the PD-MD group showed hypometabolism in lateral frontal, cingulate, and parieto-temporo-occipital cortices. Conclusions: The distribution of hypometabolic brain areas of the PD-MD group suggests that PD-MD seems to be caused by a common pathology with PD dementia. PD-SA and PD-SN seem to be caused by very mild or topographically heterogeneous cerebral dysfunction. Longitudinal clinical and neuroimaging studies are needed to define whether PD patients with single domain MCI progress to PD-MD and finally to dementia.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P: Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001;56:730–736.
  2. Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P: The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906–1911.
  3. Aarsland D, Zaccai J, Brayne C: A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005;20:1255–1263.
  4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG: Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997;9(suppl 1):65–69.
  5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  6. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
  7. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194.
  8. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment – beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med 2004;256:240–246.
  9. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH: Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 2007;22:1272–1277.
  10. Janvin CC, Larsen JP, Aarsland D, Hugdahl K: Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 2006;21:1343–1349.
  11. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ: Cortical glucose metabolism in Parkinson’s disease without dementia. Neurobiol Aging 1994;15:329–335.
  12. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ: Cortical dysfunction in non-demented Parkinson’s disease patients: a combined 31P-MRS and 18FDG-PET study. Brain 2000;123:340–352.
  13. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, Calne DB: Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 1992;49:1262–1268.
  14. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE: Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med 1997;38:797–802.
  15. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D: Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage 2007;34:714–723.
  16. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D: Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70:1470–1477.
  17. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.
  18. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J: Subthalamic dbs replaces levodopa in Parkinson’s disease: Two-year follow-up. Neurology 2002;58:396–401.
  19. Kang Y, Na DL: Seoul Neuropsychological Screening Battery. Incheon, Human Brain Research & Consulting Company, 2003.
  20. Kim H, Na DL: Normative data on the Korean version of the Boston naming test. J Clin Exp Neuropsychol 1999;21:127–133.
  21. Dujardin K, Laurent B: Dysfunction of the human memory systems: role of the dopaminergic transmission. Curr Opin Neurol 2003;16:S11–S16.
  22. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO: Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005;25:2471–2477.
  23. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR: Dopaminergic modulation of cortical function in patients with Parkinson’s disease. Ann Neurol 2002;51:156–164.
  24. Vargha-Khadem F, Gadian DG, Watkins KE, Connelly A, Van Paesschen W, Mishkin M: Differential effects of early hippocampal pathology on episodic and semantic memory. Science 1997;277:376–380.
  25. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA: Parkinson’s disease is associated with hippocampal atrophy. Mov Disord 2003;18:784–790.
  26. Summerfield C, Junque C, Tolosa E, Salgado-Pineda P, Gomez-Anson B, Marti MJ, Pastor P, Ramirez-Ruiz B, Mercader J: Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62:281–285.
  27. Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B, Brugnolo A, Canepa C, Drosos GC, Sambuceti G, Rodriguez G: Amnestic mild cognitive impairment in Parkinson’s disease: a brain perfusion spect study. Mov Disord 2009;24:414–421.
  28. Emre M: What causes mental dysfunction in Parkinson’s disease? Mov Disord 2003;18(suppl 6):S63–S71.
  29. Owen AM: Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist 2004;10:525–537.
  30. Hugdahl K, Thomsen T, Ersland L: Sex differences in visuo-spatial processing: an FMRI study of mental rotation. Neuropsychologia 2006;44:1575–1583.
  31. Crucian GP, Barrett AM, Burks DW, Riestra AR, Roth HL, Schwartz RL, Triggs WJ, Bowers D, Friedman W, Greer M, Heilman KM: Mental object rotation in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:1078–1087.
  32. Levin BE, Katzen HL: Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. Adv Neurol 2005;96:84–94.

    External Resources

  33. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243–248.
  34. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH: Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1985;48:413–421.
  35. Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y: Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease. Brain Res 1986;362:83–91.
  36. Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y: A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 1983;288:213–218.
  37. Mesulam MM, Mufson EJ, Levey AI, Wainer BH: Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170–197.
  38. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA: In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996;40:399–410.
  39. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD: Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716–1722.
  40. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–2518.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50